Drug Candidate for Neurological Diseases
Nelotanserin is a potent and selective inverse agonist of the 5-HT2A receptor that has been implicated in the pathophysiology underlying psychosis. Nelotanserin was discovered and developed by Arena, and completed Phase 1 trials in healthy volunteers and Phase 2 trials in subjects with insomnia before development was discontinued for that indication.
Under our Development, Marketing and Supply Agreement, Axovant Sciences Ltd. has exclusive worldwide rights to develop and commercialize nelotanserin, and has announced that it has initiated a double-blind, placebo-controlled, Phase 2 study in patients with either dementia with Lewy bodies, or Parkinson’s disease dementia who suffer from visual hallucinations, and intends to initiate a second trial in dementia with Lewy bodies patients experiencing REM Behavior Disorder. Axovant will be responsible for funding the development and commercialization of nelotanserin.
|Drug Candidate||Disease Area||Target||Status||Retained Rights|
|Nelotanserin*||Neurological Diseases||5HT2A Inverse Agonist||Phase 2 Trials Ongoing||Collaboration with Axovant|
|Disease Area||Neurological Diseases|
|Target||5HT2A Inverse Agonist|
|Status||Phase 2 Trials Ongoing|
|Retained Rights||Collaboration with Axovant|
*Development expenses shared with or funded by collaborators
Nelotanserin has not been approved by the US Food and Drug Administration or any other regulatory agency.